A Phase III, Open-Label, Multi-Center, Randomized Study Comparing AAA817 Plus ARPI Versus Standard of Care in Adult Participants with PSMA-Positive Metastatic Castration Resistant Prostate Cancer

Sponsor:

Novartis Corp.

Sponsor Study ID:

CAAA817B12301

CTO #:

104177

NCT Number:

NCT06855277

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Prostate

Study Objectives:

To determine whether treatment with AAA817+ARPI prolongs radiographic progression free survival (rPFS) as assessed by Prostate Cancer Working Group 3 (PCWG3)- modified RECIST v1.1, in participants with PSMA-positive mCRPC, treated with another ARPI as last treatment as compared to participants treated with investigator?s choice of standard of care.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)